Molecular mechanisms of enzalutamide resistance in prostate cancer

Eliot B. Blatt, Ganesh V. Raj

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


An estimated 30,000 men in the United States will die of metastatic prostate cancer (PCa) each year due to the development of therapy resistance, most notably resistance to second-generation antiandrogen enzalutamide. The vast majority of PCa is driven by the androgen receptor (AR). Enzalutamide is an AR antagonist, which extends patient survival and is widely used in the clinic for the treatment of castration-resistant prostate cancer (CRPC); however, many patients will have primary or develop acquired resistance and continue to progress. Characterization of the molecular mechanisms of enzalutamide resistance provides insight into potentially efficacious therapies for enzalutamide-resistant CRPC (ER-CRPC). Understanding these mechanisms is critical for the identification of biomarkers predictive of therapy resistance and the development of therapeutic strategies to target ER-CRPC.

Original languageEnglish (US)
Pages (from-to)189-197
Number of pages9
JournalCancer Drug Resistance
Issue number2
StatePublished - 2019


  • Biomarkers of drug responsiveness
  • Drug resistant cancers
  • Resistance modulation
  • Targeted therapy resistance

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'Molecular mechanisms of enzalutamide resistance in prostate cancer'. Together they form a unique fingerprint.

Cite this